ONO PHARMACEUTICAL CO., LTD. based in Osaka, JP has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-03-26

US20260083735A1

Human necessities

ABHD6 ANTAGONIST

#2 | 2026-01-01

US20260000635A1

Human necessities

THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKER

#3 | 2025-12-04

US20250368736A1

Chemistry; metallurgy

BISPECIFIC ANTIBODY

#4 | 2025-07-03

US20250214984A1

Chemistry; metallurgy

COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF

#5 | 2025-06-19

US20250197401A1

Chemistry; metallurgy

PURINONE DERIVATIVE

#6 | 2025-06-12

US20250188023A1

Chemistry; metallurgy

BENZENE DERIVATIVE

#7 | 2025-05-08

US20250145719A1

Chemistry; metallurgy

IMMUNOSUPPRESIVE AGENT

#8 | 2025-03-27

US20250099419A1

Human necessities

BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES

#9 | 2025-02-06

US20250042870A1

Chemistry; metallurgy

DP ANTAGONIST

#10 | 2025-01-30

US20250034187A1

Chemistry; metallurgy

STING AGONISTIC COMPOUND

#11 | 2024-10-03

US20240327342A1

Chemistry; metallurgy

COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY

#12 | 2024-09-26

US20240317751A1

Chemistry; metallurgy

PURINONE DERIVATIVE HYDROCHLORIDE

#13 | 2024-08-29

US20240287187A1

Chemistry; metallurgy

BISPECIFIC ANTIBODY

#14 | 2024-08-15 ✅ Patent 12,600,730 granted on 2026-04-14

US20240270755A1

Chemistry; metallurgy

SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS

#15 | 2024-08-01

US20240254226A1

Chemistry; metallurgy

CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY

#16 | 2024-05-14 ✅ Patent 11,981,747 granted on 2024-05-14

US18365828

Chemistry; metallurgy

HER2 targeting agent

#17 | 2024-03-14

US20240083899A1

Chemistry; metallurgy

PURINONE DERIVATIVE

#18 | 2024-01-11 ✅ Patent 11,981,682 granted on 2024-05-14

US20240010658A1

Chemistry; metallurgy

Substituted cyclopenta[c]pyrroles as ABHD6 antagonists

#19 | 2024-01-04 ✅ Patent 12,122,846 granted on 2024-10-22

US20240002532A1

Chemistry; metallurgy

Chimeric antigen receptor for tumor targeting

#20 | 2024-01-04

US20240002531A1

Chemistry; metallurgy

HER2 TARGETING AGENT

#21 | 2023-12-14 ✅ Patent 12,630,544 granted on 2026-05-19

US20230399323A1

Chemistry; metallurgy

NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF

#22 | 2023-10-26 ✅ Patent 12,152,049 granted on 2024-11-26

US20230339992A1

Chemistry; metallurgy

STING agonistic compound

#23 | 2023-09-07

US20230277546A1

Human necessities

AGENT FOR SUPPRESSING POST-SURGICAL CANCER RECURRENCE AND/OR METASTASIS

#24 | 2023-08-31 ✅ Patent 12,269,817 granted on 2025-04-08

US20230271952A1

Chemistry; metallurgy

Compound having KDM5 inhibitory activity and pharmaceutical use thereof

#25 | 2023-07-13 ✅ Patent 11,919,932 granted on 2024-03-05

US20230220022A1

Chemistry; metallurgy

HMGN partial peptide and cancer therapy using the same

#26 | 2023-06-22 ✅ Patent 12,201,603 granted on 2025-01-21

US20230190698A1

Human necessities

Bicyclic compound and use thereof for medical purposes

#27 | 2023-05-18

US20230151024A1

Chemistry; metallurgy

STING AGONISTIC COMPOUND

#28 | 2023-05-11

US20230143066A1

Performing operations; transporting

METHOD FOR REMOVING COLOR FROM DRUG SUBSTANCE OF PROTEIN PREPARATION

#29 | 2023-05-11

US20230141284A1

Human necessities

CANCER THERAPEUTIC METHOD

#30 | 2023-05-04

US20230138003A1

Chemistry; metallurgy

DIHYDROINDOLIZINONE DERIVATIVE

#31 | 2023-04-06 ✅ Patent 11,691,968 granted on 2023-07-04

US20230109293A1

Chemistry; metallurgy

Compound having KDM5 inhibitory activity and pharmaceutical use thereof

#32 | 2022-12-08 ✅ Patent 12,630,510 granted on 2026-05-19

US20220388955A1

Chemistry; metallurgy

EP2 ANTAGONIST

#33 | 2022-11-24

US20220372148A1

Chemistry; metallurgy

A PHARMACEUTICAL COMPOSITION FOR TREATING HEMATOLOGICAL CANCER

#34 | 2022-11-17

US20220363684A1

Chemistry; metallurgy

PURINONE DERIVATIVE

#35 | 2022-09-29

US20220306640A1

Chemistry; metallurgy

HYDANTOIN DERIVATIVE

#36 | 2022-09-15 ✅ Patent 12,459,890 granted on 2025-11-04

US20220289675A1

Chemistry; metallurgy

SALT AND CRYSTAL FORM OF COMPOUND HAVING AGONISTIC ACTIVITY TO S1P5 RECEPTOR

#37 | 2022-09-08 ✅ Patent 12,571,799 granted on 2026-03-10

US20220283167A1

Physics

BIOMARKERS FOR DETERMINING THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS

#38 | 2022-06-30

US20220204468A1

Chemistry; metallurgy

DP ANTAGONIST

#39 | 2022-06-16 ✅ Patent 12,325,746 granted on 2025-06-10

US20220185885A1

Chemistry; metallurgy

BISPECIFIC ANTIBODY

#40 | 2022-06-09 ✅ Patent 11,897,885 granted on 2024-02-13

US20220177474A1

Chemistry; metallurgy

Purinone derivative hydrochloride

#41 | 2022-04-21 ✅ Patent 12,036,204 granted on 2024-07-16

US20220117933A1

Human necessities

Pharmaceutical composition for treating tumor

#42 | 2022-03-24 ✅ Patent 12,258,308 granted on 2025-03-25

US20220089532A1

Chemistry; metallurgy

Benzene derivative

#43 | 2022-03-24

US20220087987A1

Human necessities

A METHOD FOR TREATING SWI/SNF COMPLEX-DEFICIENT CANCERS COMPRISING GLUTATHIONE (GSH) METABOLIC PATHWAY INHIBITOR

#44 | 2022-02-24 ✅ Patent 12,049,445 granted on 2024-07-30

US20220055986A1

Chemistry; metallurgy

Compounds having S1P5 receptor agonistic activity

#45 | 2022-02-17 ✅ Patent 12,497,377 granted on 2025-12-16

US20220048881A1

Chemistry; metallurgy

TRICYCLIC SPIRO COMPOUND

#46 | 2022-02-03 ✅ Patent 11,319,296 granted on 2022-05-03

US20220033371A1

Chemistry; metallurgy

DP antagonist

#47 | 2022-01-27 ✅ Patent 12,234,289 granted on 2025-02-25

US20220025051A1

Chemistry; metallurgy

Immunosuppresive agent

#48 | 2022-01-13 ✅ Patent 12,447,150 granted on 2025-10-21

US20220008421A1

Human necessities

TREATMENT OF CANCER BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY

#49 | 2021-12-02

US20210371379A1

Chemistry; metallurgy

NOVEL SALT OF 4-({(4S)-1-(4-CARBAMIMIDOYLBENZOYL)-4-[4(METHYLSULFONYL)PIPERAZIN-1-YL]-L-PROLYL}AMINO) BENZOIC ACID AND NOVEL CRYSTAL FORM THEREOF

#50 | 2021-11-25 ✅ Patent 11,919,917 granted on 2024-03-05

US20210363166A1

Chemistry; metallurgy

Sting agonistic compound

#51 | 2021-11-11 ✅ Patent 11,851,428 granted on 2023-12-26

US20210347773A1

Chemistry; metallurgy

Activator of TREK (TWIK RElated Kchannels) channels

#52 | 2021-10-28 ✅ Patent 12,091,461 granted on 2024-09-17

US20210332134A1

Chemistry; metallurgy

Bispecific antibody

#53 | 2021-10-28 ✅ Patent 11,261,154 granted on 2022-03-01

US20210332009A1

Chemistry; metallurgy

Benzene derivative

#54 | 2021-08-19 ✅ Patent 11,130,773 granted on 2021-09-28

US20210253615A1

Chemistry; metallurgy

STING agonistic compound

#55 | 2021-07-22

US20210222177A1

Chemistry; metallurgy

THERAPEUTIC AGENT FOR CARTILAGE-RELATED DISEASE

#56 | 2021-07-15 ✅ Patent 11,091,550 granted on 2021-08-17

US20210214441A1

Chemistry; metallurgy

Bispecific antibody

#57 | 2021-07-01 ✅ Patent 12,240,903 granted on 2025-03-04

US20210198361A1

Chemistry; metallurgy

Biomarkers for determining the effectiveness of immune checkpoint inhibitors

#58 | 2021-06-10 ✅ Patent 11,617,733 granted on 2023-04-04

US20210169842A1

Human necessities

Bicyclic compound and use thereof for medical purposes

#59 | 2021-06-03 ✅ Patent 11,479,550 granted on 2022-10-25

US20210163466A1

Chemistry; metallurgy

EP4 antagonist

#60 | 2021-05-20

US20210147403A1

Chemistry; metallurgy

SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES

#61 | 2021-04-22

US20210113568A1

Human necessities

PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT

#62 | 2021-03-25 ✅ Patent 11,198,672 granted on 2021-12-14

US20210087141A1

Chemistry; metallurgy

Compounds having S1P5 receptor agonistic activity

#63 | 2021-03-25

US20210085636A1

Human necessities

THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKER

#64 | 2021-01-14 ✅ Patent 11,292,795 granted on 2022-04-05

US20210009593A1

Chemistry; metallurgy

Purinone derivative hydrochloride

#65 | 2021-01-14 ✅ Patent 11,566,027 granted on 2023-01-31

US20210009586A1

Chemistry; metallurgy

Dihydroindolizinone derivative

#66 | 2021-01-07

US20210003579A1

Physics

METHOD FOR ASSISTING DETERMINATION OF EFFICACY OF IMMUNE CHECKPOINT INHIBITOR

#67 | 2020-12-31 ✅ Patent 11,572,393 granted on 2023-02-07

US20200407408A1

Chemistry; metallurgy

HMGN partial peptide and cancer therapy using the same

#68 | 2020-12-17

US20200392110A1

Chemistry; metallurgy

QUINOLINE DERIVATIVE

#69 | 2020-10-22 ✅ Patent 11,826,363 granted on 2023-11-28

US20200330453A1

Human necessities

Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient

#70 | 2020-10-15

US20200325453A1

Chemistry; metallurgy

METHOD FOR PRODUCING NAÏVE PLURIPOTENT STEM CELLS

#71 | 2020-09-03 ✅ Patent 10,905,737 granted on 2021-02-02

US20200276259A1

Human necessities

Methods of producing anamorelin hydrochloride having controlled chloride content

#72 | 2020-06-04 ✅ Patent 12,186,392 granted on 2025-01-07

US20200171153A1

Human necessities

Combination therapy of an anti CD20 antibody with a BTK inhibitor

#73 | 2020-05-21

US20200157050A1

Chemistry; metallurgy

KCNQ2-5 CHANNEL ACTIVATOR

#74 | 2020-05-07 ✅ Patent 10,815,233 granted on 2020-10-27

US20200140435A1

Chemistry; metallurgy

Dihydroindolizinone derivative

#75 | 2020-05-07

US20200138945A1

Human necessities

Monoclonal Antibodies to Programmed Death 1 (PD-1)

#76 | 2020-04-02 ✅ Patent 11,192,876 granted on 2021-12-07

US20200102284A1

Chemistry; metallurgy

Tricyclic spiro compound

#77 | 2020-03-26 ✅ Patent 10,940,134 granted on 2021-03-09

US20200093781A1

Human necessities

Bicyclic compound and use thereof for medical purposes

#78 | 2020-02-27

US20200062846A1

Chemistry; metallurgy

IMMUNOPOTENTIATIVE COMPOSITION

#79 | 2020-02-13

US20200048256A1

Chemistry; metallurgy

PURINONE DERIVATIVE

#80 | 2020-01-02 ✅ Patent 10,676,462 granted on 2020-06-09

US20200002313A1

Chemistry; metallurgy

Quinoline derivative

#81 | 2020-01-02

US20200000816A1

Human necessities

COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF

#82 | 2020-01-02 ✅ Patent 11,052,091 granted on 2021-07-06

US20200000810A1

Human necessities

BRK inhibitory compound

#83 | 2019-12-26 ✅ Patent 10,836,747 granted on 2020-11-17

US20190389837A1

Chemistry; metallurgy

Ethane-sulfonate salt of quinoline derivative

#84 | 2019-11-21 ✅ Patent 10,550,119 granted on 2020-02-04

US20190352304A1

Chemistry; metallurgy

Dihydroindolizinone derivative

#85 | 2019-10-24 ✅ Patent 11,046,683 granted on 2021-06-29

US20190322662A1

Chemistry; metallurgy

Activator of TREK (TWIK RElated K channels) channels

#86 | 2019-10-17 ✅ Patent 11,512,087 granted on 2022-11-29

US20190315756A1

Chemistry; metallurgy

BRK inhibitory compound

#87 | 2019-10-17 ✅ Patent 10,807,981 granted on 2020-10-20

US20190315748A1

Chemistry; metallurgy

Purinone derivative hydrochloride

#88 | 2019-10-17 ✅ Patent 10,899,729 granted on 2021-01-26

US20190315705A1

Chemistry; metallurgy

Method for producing bicyclic compound

#89 | 2019-08-29 ✅ Patent 10,882,855 granted on 2021-01-05

US20190263795A1

Chemistry; metallurgy

Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases

#90 | 2019-08-22 ✅ Patent 11,065,226 granted on 2021-07-20

US20190255013A1

Human necessities

Combination comprising EP4 antagonist and immune checkpoint inhibitor

#91 | 2019-08-01 ✅ Patent 10,576,122 granted on 2020-03-03

US20190231843A1

Human necessities

Methods of producing anamorelin hydrochloride having controlled chloride content

#92 | 2019-08-01 ✅ Patent 10,765,676 granted on 2020-09-08

US20190231777A1

Human necessities

Trk-inhibiting compound

#93 | 2019-06-06 ✅ Patent 10,487,085 granted on 2019-11-26

US20190169192A1

Chemistry; metallurgy

Purinone derivative

#94 | 2019-05-09 ✅ Patent 10,501,442 granted on 2019-12-10

US20190135785A1

Chemistry; metallurgy

Quinoline derivative

#95 | 2019-05-02 ✅ Patent 10,617,667 granted on 2020-04-14

US20190125720A1

Human necessities

Method for treating brain tumors

#96 | 2019-04-04

US20190099413A1

Human necessities

DRUG FOR CANCER THERAPY CHARACTERIZED IN THAT AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR ARE ADMINISTERED IN COMBINATION

#97 | 2019-02-21 ✅ Patent 10,426,778 granted on 2019-10-01

US20190054091A1

Human necessities

Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma

#98 | 2019-01-31 ✅ Patent 10,730,830 granted on 2020-08-04

US20190031605A1

Chemistry; metallurgy

Tetrahydronaphthalene derivative

#99 | 2019-01-31 ✅ Patent 10,835,520 granted on 2020-11-17

US20190030010A1

Human necessities

Phenyl derivative

#100 | 2019-01-03 ✅ Patent 10,300,105 granted on 2019-05-28

US20190000914A1

Human necessities

Methods of producing anamorelin hydrochloride having controlled chloride content

Also check out ONO PHARMACEUTICAL CO., LTD.'s (Osaka, Japan) applicant profile with 150 patent applications submitted.

AssigneeID:

7091 ⎘